GleamWall
中文EN

FBLG FibroBiologics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1958777 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY11.3%
TTM EPS YoY169.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-1,696.9%
ROA-211.8%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets73.2%
Debt / equity0.00x
Current ratio1.22x
Interest coverage-71.97x

Cash quality & payout

Operating cash flow / net income0.83x
Accruals ratio-36.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$2.08M$1.66M$2.95M$797,000$2.79M$2.04M$1.78M$1.36M
SG&A expense$2.00M$2.38M$2.12M$1.79M$2.25M$2.45M$2.75M$2.36M
Operating income-$4.07M-$4.03M-$5.07M-$2.59M-$5.04M-$4.49M-$4.53M-$3.71M
Interest expense$4,000$7,000$4,000$204,000$0$0$0$6,000
Income tax$0$0$0$0$0$0$0$0
Net income-$4.05M-$4.12M-$5.00M-$3.24M-$5.78M-$4.66M-$4.97M-$3.10M
EBITDA-$4.00M-$3.97M-$5.00M-$2.52M-$4.97M-$4.43M-$4.48M-$3.67M
EPS (basic)-0.38-0.66-1.33—-2.68-2.41-2.71—
EPS (diluted)-0.38-0.66-1.33—-2.68-2.41-2.71—
Weighted avg. shares (diluted)10.59M6.27M3.77M—2.15M1.93M1.83M—
Balance sheet
Cash & equivalents$1.17M$3.52M$1.48M$4.89M$4.87M$8.85M$8.67M$13.98M
Current assets$4.78M$5.85M$2.90M$6.35M$5.24M$10.18M$9.33M$14.23M
PP&E, net$661,000$710,000$776,000$842,000$908,000$967,000$814,000$824,000
Total assets$6.75M$7.93M$5.94M$9.62M$8.74M$13.91M$11.43M$16.45M
Current liabilities$3.93M$2.21M$1.83M$1.76M$6.72M$10.96M$8.21M$12.73M
Total liabilities$4.94M$3.29M$3.34M$3.46M$8.62M$13.05M$9.08M$13.71M
Shareholders' equity$1.81M$4.64M$2.60M$6.16M$125,000$860,000$2.35M$2.73M
Cash flow statement
Operating cash flow-$2.75M-$3.29M-$4.36M-$3.16M-$3.97M-$3.98M-$5.28M-$3.07M
Capital expenditure$18,000$0$0$0$6,000$213,000$43,000$99,000
Free cash flow-$2.77M-$3.29M-$4.36M-$3.16M-$3.98M-$4.20M-$5.32M-$3.17M
Investing cash flow-$18,000$0$0$0-$6,000-$213,000-$43,000-$99,000
Financing cash flow$426,000$5.32M$952,000$3.19M$0$4.38M$0$9.33M
Depreciation & amortization$66,000$66,000$66,000$66,000$65,000$60,000$53,000$47,000
Stock-based compensation$671,000$707,000$694,000$702,000$704,000$729,000$551,000$544,000

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.